Used in cancer immunotherapy to block the PD-L1 protein on tumor cells, preventing suppression of T-cell activity and enhancing the immune system’s ability to detect and destroy cancer cells. Shows therapeutic potential in treating various solid tumors, including non-small cell lung cancer, melanoma, and bladder cancer. Also employed in diagnostic assays to detect PD-L1 expression levels in tumor tissues, aiding in patient selection for immunotherapy. Investigated in combination with other immune checkpoint inhibitors to improve clinical outcomes.